Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This national English study reveals a significant increase in pre-existing cardiovascular disease among patients at cancer diagnosis over two decades, projecting nearly half will have cardiovascular comorbidities by 2050, underlining urgent
The 2026 ESC clinical consensus outlines creation of multidisciplinary Women’s Heart Centres to close gaps in diagnosis, management, and research for women’s cardiovascular disease across the life course.
The EMPATICC trial explored heart failure therapy for patients with advanced cancer in palliative care. While it did not meet its primary endpoint for self-care ability due to high mortality, survivors showed improved cardiac biomarkers and
This study identifies CXCR6+ T cells as the primary drivers of immune checkpoint inhibitor-induced myocarditis, especially with anti-LAG-3/PD-1 combinations. Researchers demonstrate that targeting the CXCR6-CXCL16 axis can reduce cardiac in
A randomized clinical trial indicates that the GnRH agonist leuprolide significantly accelerates coronary plaque progression compared to the antagonist relugolix in men with prostate cancer, suggesting a potential biological mechanism for d
Emerging evidence identifies a bidirectional link between breast cancer and pulmonary arterial hypertension (PAH) driven by BMPR2 signaling and IL-1β-mediated inflammation. This study suggests breast cancer may serve as a critical second hi
A randomized clinical trial demonstrates that the GnRH agonist leuprolide leads to significantly greater coronary plaque progression, specifically noncalcified plaque, compared to the antagonist relugolix in men with prostate cancer, offeri
A prospective study reveals that PM2.5 and ozone exposure significantly exacerbate cardiac dysfunction and adverse remodeling in breast cancer patients receiving anthracyclines or trastuzumab, doubling the risk of clinical LVEF decline.
A breakthrough study reveals that osimertinib-induced cardiac dysfunction is driven by reversible sarcomere disarray via the GATA4-MYLK3-MYL2 signaling axis, suggesting that myosin activators could mitigate heart failure risk in lung cancer
The Cardiac CARE trial reveals that high-sensitivity cardiac troponin I levels do not correlate with cumulative anthracycline dose and only weakly predict subsequent declines in left ventricular function, challenging existing risk-stratific
The SARAH trial demonstrates that sacubitril-valsartan significantly reduces subclinical left ventricular dysfunction in patients with elevated troponin during anthracycline chemotherapy, potentially offering a new cardioprotective strategy
A 2025 meta-analysis of 9,538 patients found trastuzumab emtansine (T‑DM1) carries the lowest incidence of LVEF decline (0.94%), while trastuzumab deruxtecan (T‑DXd) and trastuzumab-based combinations show similar, modest rates (≈4–5%). Tri
An expert summary of the 2025 ICS position statement on immune checkpoint inhibitor–associated cardiovascular toxic effects, with practical diagnostic and treatment guidance for clinicians and researchers.
A novel risk prediction model for 10-year heart failure or cardiomyopathy offers tailored cardiac management strategies for women undergoing breast cancer therapy.